Soliman EZ, et al. - Given a specifically high risk for atrial fibrillation (AF) among patients with hypertension who develop atrial premature complexes (APCs), researchers determined medications as well as modifiable risk factors that could decrease AF risk imposed by the presence of APCs in such a high-risk population. The participants were selected from the REGARDS study and included 4,331 individuals, in total, who were treated for hypertension and were free of AF and cardiovascular disease at the time of enrollment (2003-2007). A median follow-up of 9.4 years was performed, which revealed AF development in 9.9% (n = 429) of the participants. The likelihood of developing AF was more than twice among participants with APCs vs those without. Experts noted that a reduction in the significant AF risk related to APCs in patients with hypertension could potentially be achieved by treating these patients with angiotensin-II receptor blockers and statins along with reducing blood pressure and managing diabetes.